Regarding the Abstract section:
a) From this text we don't know, where iNKT and IL-10 concentration were tested, in a blood or BAL?
2. Regarding the Introduction section: a) Authors should describe a role of iNK-cells in the context of immunity, especially in sarcoidosis. b) Authors should write about immune response in blood and in lungs because there is an opposite immunological response in peripheral blood and in the lung. c) IL-10 level in a peripheral blood from SA patients is increased in many studies, why in the current study it was decreased? In some studies, a low production of IL-10 was present also in TB.We know that increased and chronic TNF-α and IL-6 production induces a secretion of anty-proinflammatory IL-10. Comments to the Author Major comments: 1. Based on the methods section, there appears to be an important typo in the second paragraph of the results section where there is reference to "negative selection" of monocytes. Please clarify as whether the study involved negative or positive selection seems critical to this study……the text in question is as follows: "We next questioned if IL-10-producing monocytes suppressed T cell proliferation. PBMCs were isolated from healthy individuals (n=12) and CD14+ cells were first removed using CD14 MACS bead positive selection system to provide a monocyte-free cell system for subsequent addition of fixed numbers of monocytes. These peripheral blood lymphocytes (PBL) were then CFSE-stained, and allogeneic monocyte-derived DCs were added [1:4, DC:PBL]. Autologous CD14+ monocytes (generated using CD14 MACS beads negative selection) or CD19+ B cells as control [1:1, monocytes (or B cells):PBL] were then added."
2. This reviewer has concerns regarding the authors' composite score. CXR manifestations in sarcoidosis connote severity of disease, not necessarily activity of disease. BAL lymphocytosis is an accepted measure of disease "activity". Also, the authors' composite measurement has not been validated which they state in the text: "no validated universal score currently exists" so why do the authors think that their score/measurement is the "best"? Further, how did the authors arrive at the score cut offs between low and high disease activity? Why not use the median value instead? The manuscript is very interesting but it needs some improvements: Important question is: if the Authors repeat the same study using CD14+CD16+ monocytes, they will obtain a low level of Il-10? Probably not. It is well known that in contrast to CD14+CD16+ monocytes, CD14+CD16-produces a low level of IL-10.
The study was performed by MACS bead CD14 negative selection kit. This kit isolates CD14+ cells without touching CD14+ cells. We optimised this kit with Miltenyi in order to include CD16+CD14+ monocytes (the original kit had CD16 mAbs which meant that CD16+ cells including CD14+CD16+ monocytes would have been depleted). Thus our monocytes contained both CD16+ and CD16-populations. Hardly any of the CD16+ monocytes produced IL-10 after LPS stimulation (we showed this in Figure 1c ). These are all freshly isolated monocytes used immediately (ie not thawed from frozen). We have made this clearer in view of this reviewer's comments.
a) From this text we don't know, where iNKT and IL-10 concentration were tested, in a blood or BAL? Apologies, these are from blood -this is now in the abstract. 
Peer review correspondence
Yes, agree -we didn't put it in originally to keep the introduction succinct and targeted but we agree it would be informative. Now added in (page 3). c) IL-10 level in a peripheral blood from SA patients is increased in many studies, why in the current study it was decreased? In some studies, a low production of IL-10 was present also in TB. We know that increased and chronic TNF-α and IL-6 production induces a secretion of anty-proinflammatory IL-10.
Most studies refer to IL-10 levels in bronchoalveolar lavage and even then the levels were low, and almost no studies compared sarcoidosis patients with healthy controls (mainly between acute and chronic). Data on IL-10 in peripheral blood in sarcoidosis is conflicting with some reports of it being reduced and others increased when measured directly in whole blood or serum in which case, the source of the IL-10 is unclear/ multiple. We are not commenting on serum IL-10 levels, rather the IL-10 production by a subset cells (monocytes) in the peripheral blood. Thank you. We were particularly interested in the monocytes in the circulation and not in the BAL because we were focusing on the upstream behaviour of monocytes before these cells migrate to the lungs or other organs. This is to provide us with a means of potentially addressing altered behaviour in these monocytes before they differentiate into macrophage or contribute to granuloma formation. The phenotype of monocytes in the peripheral blood was extensively studied, with particular focus on identifying surface markers/ other phenotypic characteristics for the IL-10 producing subset. None of the following expression: CD11b, CD11c CD14, CD15, CD16, CD32, CD62l, CD115, CD163, CCR2, CX3CR1 and HLADR were increased or reduced in the IL-10 producing subset (Figure 1c We have tested both CD14+CD16+ and CD14+CD16-, ofcourse! They are in the same panel of mAbs we used to examine whether the there are any markers that would help us identify the IL-10 producing monocytes (see figure 1c) . Sorry this is not clear -we have made it clearer by explaining that we have used these mAbs to determine it the IL-10 expressing monocytes expressed any of these markers. As per response to comment (1), hardly any of the CD16+ monocytes produced IL-10 after LPS stimulation.
d) The Discussion section is too long and it is not concrete; there are a lot of hypotheses Agree -have cut down.
Reviewer: 2
Comments to the Author Major comments:
1. Based on the methods section, there appears to be an important typo in the second paragraph of the results section where there is reference to "negative selection" of monocytes. Please clarify as whether the study involved negative or positive selection seems critical to this study……the text in question is as follows: "We next questioned if IL-10-producing monocytes suppressed T cell proliferation. PBMCs were isolated from healthy individuals (n=12) and CD14+ cells were first removed using CD14 MACS bead positive selection system to provide a monocyte-free cell system for subsequent addition of fixed numbers of monocytes. These peripheral blood lymphocytes (PBL) were then CFSE-stained, and allogeneic monocyte-derived DCs were added [1:4, DC:PBL]. Autologous CD14+ monocytes (generated using CD14 PBMCs were isolated from healthy individuals (n=12) and CD14+ cells were first removed using CD14 MACS bead positive selection system to provide a monocyte-free cell system for subsequent addition of fixed numbers of monocytes…', the CD14+ cells have to be removed from the PBMC in order that the there are no monocytes in these cells (the 'monocyte-free cell system'). This necessarily **has** to be done by CD14 positive selection. These monocytes are then discarded. Then, to add in a controlled and standard number of monocytes, we derived allogeneic monocytes using CD14 negative selection and added this into the monocyte-free cell system, as in this part of the statement "…Autologous CD14+ monocytes (generated using CD14 MACS beads negative selection) or CD19+ B cells as control [1:1, monocytes (or B cells):PBL] were then added."
2. This reviewer has concerns regarding the authors' composite score. CXR manifestations in sarcoidosis connote severity of disease, not necessarily activity of disease. BAL lymphocytosis is an accepted measure of disease "activity". Also, the authors' composite measurement has not been validated which they state in the text: "no validated universal score currently exists" so why do the authors think that their score/measurement is the "best"? Further, how did the authors arrive at the score cut offs between low and high disease activity? Why not use the median value instead?
Yes, apologies -in retrospect we agree that we should not have used the word 'best' because indeed validation of this has not been published. We have however, since validated this against BAL lymphocytosis, sol-IL2r levels, and abnormalities on high resolution CT scan; but this has not been published yet. So, we have changed the word 'best' to ' a defined and standardized' quantification of disease activity. The high and low score cut offs were arbitrary. We have now put in the whole range of disease activity score in order to remove the uncertainties over the definition of high and low activity. This showed a highly significant correlation between proportion of IL-10+ monocytes (and IL-10 levels in culture supernatant) and the disease activity score. 8. Figure legend 3B . This is not technically a correlation Thank you, agree. In fact figure 3B and 3C are now modified to remove the arbitrary division to low and high activity. We have amended legend accordingly.
Second Editorial Decision -17 March 2014
Dear Dr. Ho,
